Tenascin C in metastasis: A view from the invasive front

References

• Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006; 127:679-95; PMID:17110329; http://dx.doi.org/10.1016/j.cell.2006.11.001
   PubMed Web of Science ®Google Scholar
• Vanharanta S, Massague J. Origins of metastatic traits. Cancer cell 2013; 24:410-21; PMID:24135279; http://dx.doi.org/10.1016/j.ccr.2013.09.007
   PubMed Web of Science ®Google Scholar
• Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9:239-52; PMID:19279573; http://dx.doi.org/10.1038/nrc2618
   PubMed Web of Science ®Google Scholar
• Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011; 17:320-9; PMID:21383745; http://dx.doi.org/10.1038/nm.2328
   PubMed Web of Science ®Google Scholar
• Oskarsson T, Batlle E, Massague J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 2014; 14:306-21; PMID:24607405; http://dx.doi.org/10.1016/j.stem.2014.02.002
   PubMed Web of Science ®Google Scholar
• Hynes RO. The extracellular matrix: not just pretty fibrils. Science 2009; 326:1216-9; PMID:19965464; http://dx.doi.org/10.1126/science.1176009
   PubMed Web of Science ®Google Scholar
• Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol 2011; 3:1-24; PMID:21917992.
   PubMed Web of Science ®Google Scholar
• Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 1983; 43:2796-805; PMID:6342760
   PubMed Web of Science ®Google Scholar
• Chiquet M, Fambrough DM. Chick myotendinous antigen. II. A novel extracellular glycoprotein complex consisting of large disulfide-linked subunits. J Cell Biol 1984; 98:1937-46; PMID:6202699; http://dx.doi.org/10.1083/jcb.98.6.1937
   PubMed Web of Science ®Google Scholar
• Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000; 218:235-59; PMID:10842355; http://dx.doi.org/10.1002/(SICI)1097-0177(200006)218:2%3c235::AID-DVDY2%3e3.0.CO;2-G
   PubMed Web of Science ®Google Scholar
• Hancox RA, Allen MD, Holliday DL, Edwards DR, Pennington CJ, Guttery DS, Shaw JA, Walker RA, Pringle JH, Jones JL. Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 2009; 11:R24; PMID:19405959; http://dx.doi.org/10.1186/bcr2251
   PubMed Web of Science ®Google Scholar
• Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 1986; 47:131-9; PMID:2428505; http://dx.doi.org/10.1016/0092-8674(86)90374-0
   PubMed Web of Science ®Google Scholar
• Tucker RP, Chiquet-Ehrismann R. The regulation of tenascin expression by tissue microenvironments. Biochim Biophys Acta 2009; 1793:888-92; PMID:19162090; http://dx.doi.org/10.1016/j.bbamcr.2008.12.012
   PubMed Web of Science ®Google Scholar
• Chiquet-Ehrismann R, Orend G, Chiquet M, Tucker RP, Midwood KS. Tenascins in stem cell niches. Matrix Biol 2014; 37:112-23.
   PubMed Web of Science ®Google Scholar
• Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal 2009; 3:287-310; PMID:19838819; http://dx.doi.org/10.1007/s12079-009-0075-1
   PubMed Web of Science ®Google Scholar
• Jones PL, Boudreau N, Myers CA, Erickson HP, Bissell MJ. Tenascin-C inhibits extracellular matrix-dependent gene expression in mammary epithelial cells. Localization of active regions using recombinant tenascin fragments. J Cell Sci 1995; 108 (Pt 2):519-27; PMID:7539436
   PubMed Web of Science ®Google Scholar
• McDaniel SM, Rumer KK, Biroc SL, Metz RP, Singh M, Porter W, Schedin P. Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am J Pathol 2006; 168:608-20; PMID:16436674; http://dx.doi.org/10.2353/ajpath.2006.050677
   PubMedGoogle Scholar
• Schedin P. Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer 2006; 6:281-91; PMID:16557280; http://dx.doi.org/10.1038/nrc1839
   PubMed Web of Science ®Google Scholar
• Maseruka H, Bonshek RE, Tullo AB. Tenascin-C expression in normal, inflamed, and scarred human corneas. Br J Ophthalmol 1997; 81:677-82; PMID:9349157; http://dx.doi.org/10.1136/bjo.81.8.677
   PubMedGoogle Scholar
• Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett 2006; 244:143-63; PMID:16632194; http://dx.doi.org/10.1016/j.canlet.2006.02.017
   PubMed Web of Science ®Google Scholar
• Midwood KS, Hussenet T, Langlois B, Orend G. Advances in tenascin-C biology. Cell Mol Life Sci 2011; 68:3175-99; PMID:21818551; http://dx.doi.org/10.1007/s00018-011-0783-6
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855
   PubMed Web of Science ®Google Scholar
• Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; 5:591-602; PMID:16056258; http://dx.doi.org/10.1038/nrc1670
   PubMed Web of Science ®Google Scholar
• Mackie EJ, Chiquet-Ehrismann R, Pearson CA, Inaguma Y, Taya K, Kawarada Y, Sakakura T. Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc Natl Acad Sci U S A 1987; 84:4621-5; PMID:2440026; http://dx.doi.org/10.1073/pnas.84.13.4621
   PubMed Web of Science ®Google Scholar
• Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massagué J. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436:518-24; PMID:16049480; http://dx.doi.org/10.1038/nature03799
   PubMed Web of Science ®Google Scholar
• Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massagué J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451:147-52; PMID:18185580; http://dx.doi.org/10.1038/nature06487
   PubMed Web of Science ®Google Scholar
• Gurbuz I, Ferralli J, Roloff T, Chiquet-Ehrismann R, Asparuhova MB. SAP domain-dependent Mkl1 signaling stimulates proliferation and cell migration by induction of a distinct gene set indicative of poor prognosis in breast cancer patients. Mol Cancer 2014; 13:22; PMID:24495796; http://dx.doi.org/10.1186/1476-4598-13-22
   PubMedGoogle Scholar
• Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ, Pavlidis N. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 2002; 38:2362-70; PMID:12460779; http://dx.doi.org/10.1016/S0959-8049(02)00210-1
   PubMed Web of Science ®Google Scholar
• Dandachi N, Hauser-Kronberger C, More E, Wiesener B, Hacker GW, Dietze O, Wirl G. Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. J Pathol 2001; 193:181-9; PMID:11180164; http://dx.doi.org/10.1002/1096-9896(2000)9999:9999%3c::AID-PATH752%3e3.0.CO;2-V
   PubMedGoogle Scholar
• Ferguson JE, Schor AM, Howell A, Ferguson MW. Tenascin distribution in the normal human breast is altered during the menstrual cycle and in carcinoma. Differentiation 1990; 42:199-207; PMID:1692795; http://dx.doi.org/10.1111/j.1432-0436.1990.tb00762.x
   PubMed Web of Science ®Google Scholar
• Shoji T, Kamiya T, Tsubura A, Hatano T, Sakakura T, Yamamoto M, Morii S. Immunohistochemical staining patterns of tenascin in invasive breast carcinomas. Virchows Archiv A Pathol Anat Histopathol 1992; 421:53-6; PMID:1378984; http://dx.doi.org/10.1007/BF01607139
   PubMedGoogle Scholar
• Goepel C, Buchmann J, Schultka R, Koelbl H. Tenascin-A marker for the malignant potential of preinvasive breast cancers. Gynecol Oncol 2000; 79:372-8; PMID:11104607; http://dx.doi.org/10.1006/gyno.2000.5978
   PubMedGoogle Scholar
• Jahkola T, Toivonen T, Nordling S, von Smitten K, Virtanen I. Expression of tenascin-C in intraductal carcinoma of human breast: relationship to invasion. Eur J Cancer 1998; 34:1687-92; PMID:9893653; http://dx.doi.org/10.1016/S0959-8049(98)00215-9
   PubMedGoogle Scholar
• Jahkola T, Toivonen T, Virtanen I, von Smitten K, Nordling S, von Boguslawski K, Haglund C, Nevanlinna H, Blomqvist C. Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer 1998; 78:1507-13; PMID:9836485; http://dx.doi.org/10.1038/bjc.1998.714
   PubMed Web of Science ®Google Scholar
• Ishihara A, Yoshida T, Tamaki H, Sakakura T. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin Cancer Res 1995; 1:1035-41; PMID:9816077
   PubMed Web of Science ®Google Scholar
• Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E, Massagué J. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 2011; 17:867-74; PMID:21706029; http://dx.doi.org/10.1038/nm.2379
   PubMed Web of Science ®Google Scholar
• Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, LeBaron RG, Raymond WA, Tilley WD, Horsfall DJ. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 2004; 10:2491-8; PMID:15073129; http://dx.doi.org/10.1158/1078-0432.CCR-03-0146
   PubMed Web of Science ®Google Scholar
• Keith RL, Miller YE. Lung cancer chemoprevention: current status and future prospects. Nat Rev Clin Oncol 2013; 10:334-43; PMID:23689750; http://dx.doi.org/10.1038/nrclinonc.2013.64
   PubMedGoogle Scholar
• Silacci M, Brack SS, Spath N, Buck A, Hillinger S, Arni S, Weder W, Zardi L, Neri D. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel 2006; 19:471-8; http://dx.doi.org/10.1093/protein/gzl033
   PubMed Web of Science ®Google Scholar
• Pedretti M, Soltermann A, Arni S, Weder W, Neri D, Hillinger S. Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer. Lung Cancer 2009; 64:28-33; PMID:18799229; http://dx.doi.org/10.1016/j.lungcan.2008.07.013
   PubMedGoogle Scholar
• Parekh K, Ramachandran S, Cooper J, Bigner D, Patterson A, Mohanakumar T. Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes. Lung Cancer 2005; 47:17-29; PMID:15603851; http://dx.doi.org/10.1016/j.lungcan.2004.05.016
   PubMedGoogle Scholar
• Kang H, Kiess A, Chung CH. Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol 2014; 12:11-26; PMID:25403939.
   PubMed Web of Science ®Google Scholar
• Raitz R, Martins MD, Araujo VC. A study of the extracellular matrix in salivary gland tumors. J Oral Pathol Med 2003; 32:290-6; http://dx.doi.org/10.1034/j.1600-0714.2003.00019.x
   PubMed Web of Science ®Google Scholar
• Wang Z, Han B, Zhang Z, Pan J, Xia H. Expression of angiopoietin-like 4 and tenascin C but not cathepsin C mRNA predicts prognosis of oral tongue squamous cell carcinoma. Biomarkers 2010; 15:39-46; PMID:19775228; http://dx.doi.org/10.3109/13547500903261362
   PubMed Web of Science ®Google Scholar
• Juhasz A, Bardos H, Repassy G, Adany R. Characteristic distribution patterns of tenascin in laryngeal and hypopharyngeal cancers. Laryngoscope 2000; 110:84-92; PMID:10646721; http://dx.doi.org/10.1097/00005537-200001000-00016
   PubMedGoogle Scholar
• Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014; 383:816-27; PMID:24054424; http://dx.doi.org/10.1016/S0140-6736(13)60802-8
   PubMed Web of Science ®Google Scholar
• Natali PG, Nicotra MR, Bartolazzi A, Mottolese M, Coscia N, Bigotti A, Zardi L. Expression and production of tenascin in benign and malignant lesions of melanocyte lineage. Int J Cancer 1990; 46:586-90; PMID:1698727; http://dx.doi.org/10.1002/ijc.2910460406
   PubMedGoogle Scholar
• Tuominen H, Kallioinen M. Increased tenascin expression in melanocytic tumors. J Cutan Pathol 1994; 21:424-9; PMID:7532653; http://dx.doi.org/10.1111/j.1600-0560.1994.tb00284.x
   PubMed Web of Science ®Google Scholar
• Sis B, Sagol O, Kupelioglu A, Sokmen S, Terzi C, Fuzun M, Ozer E, Bishop P. Prognostic significance of matrix metalloproteinase-2, cathepsin D, and tenascin-C expression in colorectal carcinoma. Pathol Res Pract 2004; 200:379-87; PMID:15239346; http://dx.doi.org/10.1016/j.prp.2004.02.012
   PubMedGoogle Scholar
• Emoto K, Yamada Y, Sawada H, Fujimoto H, Ueno M, Takayama T, Kamada K, Naito A, Hirao S, Nakajima Y. Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 2001; 92:1419-26; PMID:11745218; http://dx.doi.org/10.1002/1097-0142(20010915)92:6%3c1419::AID-CNCR1465%3e3.0.CO;2-J
   PubMed Web of Science ®Google Scholar
• Dueck M, Riedl S, Hinz U, Tandara A, Moller P, Herfarth C, Faissner A. Detection of tenascin-C isoforms in colorectal mucosa, ulcerative colitis, carcinomas and liver metastases. Int J Cancer 1999; 82:477-83; PMID:10404058; http://dx.doi.org/10.1002/(SICI)1097-0215(19990812)82:4%3c477::AID-IJC2%3e3.0.CO;2-5
   PubMedGoogle Scholar
• Galler K, Junker K, Franz M, Hentschel J, Richter P, Gajda M, Göhlert A, von Eggeling F, Heller R, Giavazzi R, et al. Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery. Histochem Cell Biol 2012; 137:195-204; PMID:22075565; http://dx.doi.org/10.1007/s00418-011-0886-z
   PubMedGoogle Scholar
• Schwager K, Villa A, Rosli C, Neri D, Rosli-Khabas M, Moser G. A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer. Head Neck Oncol 2011; 3:25; PMID:21548989; http://dx.doi.org/10.1186/1758-3284-3-25
   PubMedGoogle Scholar
• Mighell AJ, Thompson J, Hume WJ, Markham AF, Robinson PA. Human tenascin-C: identification of a novel type III repeat in oral cancer and of novel splice variants in normal, malignant and reactive oral mucosae. Int J Cancer 1997; 72:236-40; PMID:9219826; http://dx.doi.org/10.1002/(SICI)1097-0215(19970717)72:2%3c236::AID-IJC6%3e3.0.CO;2-S
   PubMedGoogle Scholar
• Derr LB, Chiquet-Ehrismann R, Gandour-Edwards R, Spence J, Tucker RP. The expression of tenascin-C with the AD1 variable repeat in embryonic tissues, cell lines and tumors in various vertebrate species. Differentiation 1997; 62:71-82; PMID:9404002; http://dx.doi.org/10.1046/j.1432-0436.1997.6220071.x
   PubMedGoogle Scholar
• Frey K, Fiechter M, Schwager K, Belloni B, Barysch MJ, Neri D, Dummer R. Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions. Exp Dermatol 2011; 20:685-8; PMID:21649738; http://dx.doi.org/10.1111/j.1600-0625.2011.01314.x
   PubMed Web of Science ®Google Scholar
• Berndt A, Anger K, Richter P, Borsi L, Brack S, Silacci M, Franz M, Wunderlich H, Gajda M, Zardi L, et al. Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder. J Cancer Res Clin Oncol 2006; 132:537-46; PMID:16788848; http://dx.doi.org/10.1007/s00432-006-0106-8
   PubMedGoogle Scholar
• Richter P, Tost M, Franz M, Altendorf-Hofmann A, Junker K, Borsi L, Neri D, Kosmehl H, Wunderlich H, Berndt A. B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder? J Cancer Res Clin Oncol 2009; 135:1351-8; PMID:19326143; http://dx.doi.org/10.1007/s00432-009-0576-6
   PubMedGoogle Scholar
• Wilson KE, Langdon SP, Lessells AM, Miller WR. Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours. Br J Cancer 1996; 74:999-1004; PMID:8855965; http://dx.doi.org/10.1038/bjc.1996.480
   PubMedGoogle Scholar
• Adams M, Jones JL, Walker RA, Pringle JH, Bell SC. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res 2002; 62:3289-97; PMID:12036947
   PubMed Web of Science ®Google Scholar
• Guttery DS, Hancox RA, Mulligan KT, Hughes S, Lambe SM, Pringle JH, Walker RA, Jones JL, Shaw JA. Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. Breast Cancer Res 2010; 12:R57; PMID:20678196
   PubMed Web of Science ®Google Scholar
• Moritz S, Lehmann S, Faissner A, von Holst A. An induction gene trap screen in neural stem cells reveals an instructive function of the niche and identifies the splicing regulator sam68 as a tenascin-C-regulated target gene. Stem Cells 2008; 26:2321-31; PMID:18617690; http://dx.doi.org/10.1634/stemcells.2007-1095
   PubMedGoogle Scholar
• Jensen MA, Wilkinson JE, Krainer AR. Splicing factor SRSF6 promotes hyperplasia of sensitized skin. Nat Struct Mol Biol 2014; 21:189-97; PMID:24440982; http://dx.doi.org/10.1038/nsmb.2756
   PubMed Web of Science ®Google Scholar
• Borsi L, Balza E, Castellani P, Carnemolla B, Ponassi M, Querze G, Zardi L. Cell-cycle dependent alternative splicing of the tenascin primary transcript. Cell Adhes Commun 1994; 1:307-17; PMID:7521758; http://dx.doi.org/10.3109/15419069409097262
   PubMed Web of Science ®Google Scholar
• Borsi L, Balza E, Gaggero B, Allemanni G, Zardi L. The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH. J Biol Chem 1995; 270:6243-5; PMID:7534307; http://dx.doi.org/10.1074/jbc.270.11.6243
   PubMed Web of Science ®Google Scholar
• Latijnhouwers MA, de Jongh GJ, Bergers M, de Rooij MJ, Schalkwijk J. Expression of tenascin-C splice variants by human skin cells. Arch Dermatol Res 2000; 292:446-54; PMID:11000288; http://dx.doi.org/10.1007/s004030000152
   PubMedGoogle Scholar
• Zhao Y, Young SL. TGF-β regulates expression of tenascin alternative-splicing isoforms in fetal rat lung. Am J Physiol 1995; 268:L173-80; PMID:7532367
   PubMed Web of Science ®Google Scholar
• von Holst A, Egbers U, Prochiantz A, Faissner A. Neural stem/progenitor cells express 20 tenascin C isoforms that are differentially regulated by Pax6. J Biol Chem 2007; 282:9172-81; PMID:17264084; http://dx.doi.org/10.1074/jbc.M608067200
   PubMedGoogle Scholar
• Imai K, Kusakabe M, Sakakura T, Nakanishi I, Okada Y. Susceptibility of tenascin to degradation by matrix metalloproteinases and serine proteinases. FEBS Lett 1994; 352:216-8; PMID:7523186; http://dx.doi.org/10.1016/0014-5793(94)00960-0
   PubMed Web of Science ®Google Scholar
• Siri A, Knauper V, Veirana N, Caocci F, Murphy G, Zardi L. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem 1995; 270:8650-4; PMID:7536739; http://dx.doi.org/10.1074/jbc.270.15.8650
   PubMed Web of Science ®Google Scholar
• Bell SC, Pringle JH, Taylor DJ, Malak TM. Alternatively spliced tenascin-C mRNA isoforms in human fetal membranes. Mol Hum Reprod 1999; 5:1066-76; PMID:10541570; http://dx.doi.org/10.1093/molehr/5.11.1066
   PubMedGoogle Scholar
• Tanaka R, Seki Y, Saito Y, Kamiya S, Fujita M, Okutsu H, Iyoda T, Takai T, Owaki T, Yajima H, et al. Tenascin-C-derived Peptide TNIIIA2 Highly Enhances Cell Survival and Platelet-derived Growth Factor (PDGF)-dependent Cell Proliferation through Potentiated and Sustained Activation of Integrin alpha5beta1. J Biol Chem 2014; 289:17699-708; PMID:24808173; http://dx.doi.org/10.1074/jbc.M113.546622
   PubMedGoogle Scholar
• Kusagawa H, Onoda K, Namikawa S, Yada I, Okada A, Yoshida T, Sakakura T. Expression and degeneration of tenascin-C in human lung cancers. Br J Cancer 1998; 77:98-102; PMID:9459152; http://dx.doi.org/10.1038/bjc.1998.15
   PubMed Web of Science ®Google Scholar
• Cai M, Onoda K, Takao M, Kyoko IY, Shimpo H, Yoshida T, Yada I. Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer. Clin Cancer Res 2002; 8:1152-6; PMID:11948127
   PubMed Web of Science ®Google Scholar
• Jahkola T, Toivonen T, von Smitten K, Blomqvist C, Virtanen I. Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer 1996; 69:445-7; PMID:8980244; http://dx.doi.org/10.1002/(SICI)1097-0215(19961220)69:6%3c445::AID-IJC4%3e3.0.CO;2-4
   PubMed Web of Science ®Google Scholar
• Ilmonen S, Jahkola T, Turunen JP, Muhonen T, Asko-Seljavaara S. Tenascin-C in primary malignant melanoma of the skin. Histopathology 2004; 45:405-11; PMID:15469480; http://dx.doi.org/10.1111/j.1365-2559.2004.01976.x
   PubMedGoogle Scholar
• Kaarteenaho-Wiik R, Soini Y, Pollanen R, Paakko P, Kinnula VL. Overexpression of tenascin-C in malignant pleural mesothelioma. Histopathology 2003; 42:280-91; PMID:12605648; http://dx.doi.org/10.1046/j.1365-2559.2003.01568.x
   PubMedGoogle Scholar
• Aishima S, Taguchi K, Terashi T, Matsuura S, Shimada M, Tsuneyoshi M. Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma. Mod Pathol 2003; 16:1019-27; PMID:14559985; http://dx.doi.org/10.1097/01.MP.0000086860.65672.73
   PubMedGoogle Scholar
• Chiquet-Ehrismann R, Kalla P, Pearson CA. Participation of tenascin and transforming growth factor-β in reciprocal epithelial-mesenchymal interactions of MCF7 cells and fibroblasts. Cancer Res 1989; 49:4322-5; PMID:2472877
   PubMed Web of Science ®Google Scholar
• Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer cell 2007; 11:539-54; PMID:17560335; http://dx.doi.org/10.1016/j.ccr.2007.04.017
   PubMed Web of Science ®Google Scholar
• Chiquet M, Gelman L, Lutz R, Maier S. From mechanotransduction to extracellular matrix gene expression in fibroblasts. Biochim Biophys Acta 2009; 1793:911-20; PMID:19339214; http://dx.doi.org/10.1016/j.bbamcr.2009.01.012
   PubMed Web of Science ®Google Scholar
• Yoshida T, Matsumoto E, Hanamura N, Kalembeyi I, Katsuta K, Ishihara A, Sakakura T. Co-expression of tenascin and fibronectin in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast. J Pathol 1997; 182:421-8; PMID:9306963; http://dx.doi.org/10.1002/(SICI)1096-9896(199708)182:4%3c421::AID-PATH886%3e3.0.CO;2-U
   PubMed Web of Science ®Google Scholar
• Hanamura N, Yoshida T, Matsumoto E, Kawarada Y, Sakakura T. Expression of fibronectin and tenascin-C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas. Int J Cancer 1997; 73:10-5; PMID:9334802; http://dx.doi.org/10.1002/(SICI)1097-0215(19970926)73:1%3c10::AID-IJC2%3e3.0.CO;2-4
   PubMed Web of Science ®Google Scholar
• Hindermann W, Berndt A, Borsi L, Luo X, Hyckel P, Katenkamp D, Kosmehl H. Synthesis and protein distribution of the unspliced large tenascin-C isoform in oral squamous cell carcinoma. J Pathol 1999; 189:475-80; PMID:10629546; http://dx.doi.org/10.1002/(SICI)1096-9896(199912)189:4%3c475::AID-PATH462%3e3.0.CO;2-V
   PubMedGoogle Scholar
• Mori M, Muramatsu Y, Yamada K, Shrestha P, Takai Y. Intracellular localization of tenascin in squamous cell carcinoma of oral cavity: an immunohistochemical study. Anticancer Res 1996; 16:3075-9; PMID:8920770
   PubMed Web of Science ®Google Scholar
• Kawakatsu H, Shiurba R, Obara M, Hiraiwa H, Kusakabe M, Sakakura T. Human carcinoma cells synthesize and secrete tenascin in vitro. Jpn J Cancer Res 1992; 83:1073-80; PMID:1280634; http://dx.doi.org/10.1111/j.1349-7006.1992.tb02724.x
   PubMedGoogle Scholar
• Herlyn M, Graeven U, Speicher D, Sela BA, Bennicelli JL, Kath R, Guerry D 4th. Characterization of tenascin secreted by human melanoma cells. Cancer Res 1991; 51:4853-8; PMID:1716515
   PubMed Web of Science ®Google Scholar
• Hiraiwa N, Kida H, Sakakura T, Kusakabe M. Induction of tenascin in cancer cells by interactions with embryonic mesenchyme mediated by a diffusible factor. J Cell Sci 1993; 104 ( Pt 2):289-96; PMID:7685035
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Sawada G, Kurashige J, Matsumura T, Uchi R, Ueo H, Ishibashi M, Takano Y, Akiyoshi S, Iwaya T, et al. Tumor-derived tenascin-C promotes the epithelial-mesenchymal transition in colorectal cancer cells. Anticancer Res 2013; 33:1927-34; PMID:23645740
   PubMed Web of Science ®Google Scholar
• Saupe F, Schwenzer A, Jia Y, Gasser I, Spenle C, Langlois B, Kammerer M, Lefebvre O, Hlushchuk R, Rupp T, et al. Tenascin-C downregulates wnt inhibitor dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model. Cell Rep 2013; 5:482-92; PMID:24139798; http://dx.doi.org/10.1016/j.celrep.2013.09.014
   PubMedGoogle Scholar
• Talts JF, Wirl G, Dictor M, Muller WJ, Fassler R. Tenascin-C modulates tumor stroma and monocyte/macrophage recruitment but not tumor growth or metastasis in a mouse strain with spontaneous mammary cancer. J Cell Sci 1999; 112 (Pt 12):1855-64; PMID:10341205
   PubMed Web of Science ®Google Scholar
• O'Connell JT, Sugimoto H, Cooke VG, MacDonald BA, Mehta AI, LeBleu VS, Dewar R, Rocha RM, Brentani RR, Resnick MB, et al. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci U S A 2011; 108:16002-7; PMID:21911392; http://dx.doi.org/10.1073/pnas.1109493108
   PubMed Web of Science ®Google Scholar
• Fukunaga-Kalabis M, Martinez G, Nguyen TK, Kim D, Santiago-Walker A, Roesch A, Herlyn M. Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene 2010; 29:6115-24; PMID:20729912; http://dx.doi.org/10.1038/onc.2010.350
   PubMedGoogle Scholar
• Tanaka K, Hiraiwa N, Hashimoto H, Yamazaki Y, Kusakabe M. Tenascin-C regulates angiogenesis in tumor through the regulation of vascular endothelial growth factor expression. Int J Cancer 2004; 108:31-40; PMID:14618612; http://dx.doi.org/10.1002/ijc.11509
   PubMedGoogle Scholar
• Chiquet-Ehrismann R, Kalla P, Pearson CA, Beck K, Chiquet M. Tenascin interferes with fibronectin action. Cell 1988; 53:383-90; PMID:2452695; http://dx.doi.org/10.1016/0092-8674(88)90158-4
   PubMed Web of Science ®Google Scholar
• Chiquet-Ehrismann R, Matsuoka Y, Hofer U, Spring J, Bernasconi C, Chiquet M. Tenascin variants: differential binding to fibronectin and distinct distribution in cell cultures and tissues. Cell Regul 1991; 2:927-38; PMID:1725601
   PubMedGoogle Scholar
• Huang W, Chiquet-Ehrismann R, Moyano JV, Garcia-Pardo A, Orend G. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res 2001; 61:8586-94; PMID:11731446
   PubMed Web of Science ®Google Scholar
• Wenk MB, Midwood KS, Schwarzbauer JE. Tenascin-C suppresses Rho activation. J Cell Biol 2000; 150:913-20; PMID:10953015; http://dx.doi.org/10.1083/jcb.150.4.913
   PubMed Web of Science ®Google Scholar
• Grahovac J, Becker D, Wells A. Melanoma cell invasiveness is promoted at least in part by the epidermal growth factor-like repeats of tenascin-C. J Invest Dermatol 2013; 133:210-20; PMID:22951722; http://dx.doi.org/10.1038/jid.2012.263
   PubMedGoogle Scholar
• Hashimoto Y, Kim DJ, Adams JC. The roles of fascins in health and disease. J Pathol 2011; 224:289-300; PMID:21618240; http://dx.doi.org/10.1002/path.2894
   PubMed Web of Science ®Google Scholar
• Li A, Dawson JC, Forero-Vargas M, Spence HJ, Yu X, Konig I, Anderson K, Machesky LM. The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion. Curr Biol 2010; 20:339-45; PMID:20137952; http://dx.doi.org/10.1016/j.cub.2009.12.035
   PubMed Web of Science ®Google Scholar
• Vignjevic D, Kojima S, Aratyn Y, Danciu O, Svitkina T, Borisy GG. Role of fascin in filopodial protrusion. J Cell Biol 2006; 174:863-75; PMID:16966425; http://dx.doi.org/10.1083/jcb.200603013
   PubMed Web of Science ®Google Scholar
• Tan VY, Lewis SJ, Adams JC, Martin RM. Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC Med 2013; 11:52; PMID:23442983; http://dx.doi.org/10.1186/1741-7015-11-52
   PubMed Web of Science ®Google Scholar
• Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, Massagué J. Tumor self-seeding by circulating cancer cells. Cell 2009; 139:1315-26; PMID:20064377; http://dx.doi.org/10.1016/j.cell.2009.11.025
   PubMed Web of Science ®Google Scholar
• Fischer D, Tucker RP, Chiquet-Ehrismann R, Adams JC. Cell-adhesive responses to tenascin-C splice variants involve formation of fascin microspikes. Mol Biol Cell 1997; 8:2055-75; PMID:9348542; http://dx.doi.org/10.1091/mbc.8.10.2055
   PubMedGoogle Scholar
• Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331:1559-64; PMID:21436443; http://dx.doi.org/10.1126/science.1203543
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139:871-90; PMID:19945376; http://dx.doi.org/10.1016/j.cell.2009.11.007
   PubMed Web of Science ®Google Scholar
• Tanaka S, Sumioka T, Fujita N, Kitano A, Okada Y, Yamanaka O, Flanders KC, Miyajima M, Saika S. Suppression of injury-induced epithelial-mesenchymal transition in a mouse lens epithelium lacking tenascin-C. Mol Vis 2010; 16:1194-205; PMID:20664686
   PubMed Web of Science ®Google Scholar
• Katoh D, Nagaharu K, Shimojo N, Hanamura N, Yamashita M, Kozuka Y, Imanaka-Yoshida K, Yoshida T. Binding of alphavbeta1 and alphavbeta6 integrins to tenascin-C induces epithelial-mesenchymal transition-like change of breast cancer cells. Oncogenesis 2013; 2:e65
   Web of Science ®Google Scholar
• Nagaharu K, Zhang X, Yoshida T, Katoh D, Hanamura N, Kozuka Y, Ogawa T, Shiraishi T, Imanaka-Yoshida K. Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. Am J Pathol 2011; 178:754-63; PMID:21281808; http://dx.doi.org/10.1016/j.ajpath.2010.10.015
   PubMed Web of Science ®Google Scholar
• Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, Groom AC. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998; 153:865-73; http://dx.doi.org/10.1016/S0002-9440(10)65628-3
   PubMed Web of Science ®Google Scholar
• Sivasankaran B, Degen M, Ghaffari A, Hegi ME, Hamou MF, Ionescu MC, Zweifel C, Tolnay M, Wasner M, Mergenthaler S, et al. Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer Res 2009; 69:458-65; PMID:19147558; http://dx.doi.org/10.1158/0008-5472.CAN-08-2610
   PubMedGoogle Scholar
• Beiter K, Hiendlmeyer E, Brabletz T, Hlubek F, Haynl A, Knoll C, Kirchner T, Jung A. β-Catenin regulates the expression of tenascin-C in human colorectal tumors. Oncogene 2005; 24:8200-4; PMID:16091738
   PubMed Web of Science ®Google Scholar
• Tsunoda T, Inada H, Kalembeyi I, Imanaka-Yoshida K, Sakakibara M, Okada R, Katsuta K, Sakakura T, Majima Y, Yoshida T. Involvement of large tenascin-C splice variants in breast cancer progression. Am J Pathol 2003; 162:1857-67; PMID:12759243; http://dx.doi.org/10.1016/S0002-9440(10)64320-9
   PubMed Web of Science ®Google Scholar
• Yoshida T, Yoshimura E, Numata H, Sakakura Y, Sakakura T. Involvement of tenascin-C in proliferation and migration of laryngeal carcinoma cells. Virchows Arch 1999; 435:496-500; PMID:10592053; http://dx.doi.org/10.1007/s004280050433
   PubMedGoogle Scholar
• Orend G, Huang W, Olayioye MA, Hynes NE, Chiquet-Ehrismann R. Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4. Oncogene 2003; 22:3917-26; PMID:12813465; http://dx.doi.org/10.1038/sj.onc.1206618
   PubMedGoogle Scholar
• Swindle CS, Tran KT, Johnson TD, Banerjee P, Mayes AM, Griffith L, Wells A. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol 2001; 154:459-68; PMID:11470832; http://dx.doi.org/10.1083/jcb.200103103
   PubMed Web of Science ®Google Scholar
• Van Obberghen-Schilling E, Tucker RP, Saupe F, Gasser I, Cseh B, Orend G. Fibronectin and tenascin-C: accomplices in vascular morphogenesis during development and tumor growth. Int J Dev Biol 2011; 55:511-25; PMID:21769776; http://dx.doi.org/10.1387/ijdb.103243eo
   PubMedGoogle Scholar
• Sriramarao P, Mendler M, Bourdon MA. Endothelial cell attachment and spreading on human tenascin is mediated by α 2 β 1 and α v β 3 integrins. J Cell Sci 1993; 105 (Pt 4):1001-12; PMID:7693733
   PubMed Web of Science ®Google Scholar
• Canfield AE, Schor AM. Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells. J Cell Sci 1995; 108 (Pt 2):797-809; PMID:7539439
   PubMed Web of Science ®Google Scholar
• Chung CY, Murphy-Ullrich JE, Erickson HP. Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol Biol Cell 1996; 7:883-92; PMID:8816995; http://dx.doi.org/10.1091/mbc.7.6.883
   PubMedGoogle Scholar
• Lopez-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med 2009; 1:303-14; PMID:20049734; http://dx.doi.org/10.1002/emmm.200900043
   PubMed Web of Science ®Google Scholar
• Sottile J, Hocking DC. Fibronectin polymerization regulates the composition and stability of extracellular matrix fibrils and cell-matrix adhesions. Mol Biol Cell 2002; 13:3546-59; PMID:12388756; http://dx.doi.org/10.1091/mbc.E02-01-0048
   PubMed Web of Science ®Google Scholar
• Kaariainen E, Nummela P, Soikkeli J, Yin M, Lukk M, Jahkola T, Virolainen S, Ora A, Ukkonen E, Saksela O, et al. Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion. J Pathol 2006; 210:181-91; PMID:16924594; http://dx.doi.org/10.1002/path.2045
   PubMed Web of Science ®Google Scholar
• Wight TN, Potter-Perigo S. The extracellular matrix: an active or passive player in fibrosis? Am J Physiol Gastrointest Liver Physiol 2011; 301:G950-5; PMID:21512158; http://dx.doi.org/10.1152/ajpgi.00132.2011
   PubMed Web of Science ®Google Scholar
• Blaauboer ME, Boeijen FR, Emson CL, Turner SM, Zandieh-Doulabi B, Hanemaaijer R, Smit TH, Stoop R, Everts V. Extracellular matrix proteins: a positive feedback loop in lung fibrosis? Matrix Biol 2014; 34:170-8; PMID:24291458; http://dx.doi.org/10.1016/j.matbio.2013.11.002
   PubMed Web of Science ®Google Scholar
• Imanaka-Yoshida K, Hiroe M, Nishikawa T, Ishiyama S, Shimojo T, Ohta Y, Sakakura T, Yoshida T. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest 2001; 81:1015-24; PMID:11454990; http://dx.doi.org/10.1038/labinvest.3780313
   PubMedGoogle Scholar
• Hardie WD, Korfhagen TR, Sartor MA, Prestridge A, Medvedovic M, Le Cras TD, Ikegami M, Wesselkamper SC, Davidson C, Dietsch M, et al. Genomic profile of matrix and vasculature remodeling in TGF-α induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2007; 37:309-21; PMID:17496152; http://dx.doi.org/10.1165/rcmb.2006-0455OC
   PubMed Web of Science ®Google Scholar
• Carey WA, Taylor GD, Dean WB, Bristow JD. Tenascin-C deficiency attenuates TGF-ss-mediated fibrosis following murine lung injury. Am J Physiol Lung Cell Mol Physiol 2010; 299:L785-93; PMID:20833777; http://dx.doi.org/10.1152/ajplung.00385.2009
   PubMedGoogle Scholar
• El-Karef A, Yoshida T, Gabazza EC, Nishioka T, Inada H, Sakakura T, Imanaka-Yoshida K. Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice. J Pathol 2007; 211:86-94; PMID:17121418; http://dx.doi.org/10.1002/path.2099
   PubMed Web of Science ®Google Scholar
• De Wever O, Nguyen QD, Van Hoorde L, Bracke M, Bruyneel E, Gespach C, Mareel M. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J 2004; 18:1016-8; PMID:15059978
   PubMed Web of Science ®Google Scholar
• Islam MS, Kusakabe M, Horiguchi K, Iino S, Nakamura T, Iwanaga K, Hashimoto H, Matsumoto S, Murata T, Hori M, et al. PDGF and TGF-β promote tenascin-C expression in subepithelial myofibroblasts and contribute to intestinal mucosal protection in mice. Br J Pharmacol 2014; 171:375-88; PMID:24116743; http://dx.doi.org/10.1111/bph.12452
   PubMed Web of Science ®Google Scholar
• Tamaoki M, Imanaka-Yoshida K, Yokoyama K, Nishioka T, Inada H, Hiroe M, Sakakura T, Yoshida T. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol 2005; 167:71-80; PMID:15972953; http://dx.doi.org/10.1016/S0002-9440(10)62954-9
   PubMed Web of Science ®Google Scholar
• Jacobs TW, Byrne C, Colditz G, Connolly JL, Schnitt SJ. Radial scars in benign breast-biopsy specimens and the risk of breast cancer. New Engl J Med 1999; 340:430-6; PMID:9971867; http://dx.doi.org/10.1056/NEJM199902113400604
   PubMed Web of Science ®Google Scholar
• Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med 1998; 157:1666-80; PMID:9603153; http://dx.doi.org/10.1164/ajrccm.157.5.9707141
   PubMed Web of Science ®Google Scholar
• Oberhauser AF, Marszalek PE, Erickson HP, Fernandez JM. The molecular elasticity of the extracellular matrix protein tenascin. Nat 1998; 393:181-5; PMID:9603523; http://dx.doi.org/10.1038/30270
   PubMedGoogle Scholar
• Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, Drexler S, Sofat N, Kashiwagi M, Orend G, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009; 15:774-80; PMID:19561617; http://dx.doi.org/10.1038/nm.1987
   PubMed Web of Science ®Google Scholar
• Patel L, Sun W, Glasson SS, Morris EA, Flannery CR, Chockalingam PS. Tenascin-C induces inflammatory mediators and matrix degradation in osteoarthritic cartilage. BMC Musculoskelet Disord 2011; 12:164; PMID:21762512; http://dx.doi.org/10.1186/1471-2474-12-164
   PubMed Web of Science ®Google Scholar
• Puente Navazo MD, Valmori D, Ruegg C. The alternatively spliced domain TnFnIII A1A2 of the extracellular matrix protein tenascin-C suppresses activation-induced T lymphocyte proliferation and cytokine production. J Immunol 2001; 167:6431-40; PMID:11714809; http://dx.doi.org/10.4049/jimmunol.167.11.6431
   PubMedGoogle Scholar
• Hauzenberger D, Olivier P, Gundersen D, Ruegg C. Tenascin-C inhibits beta1 integrin-dependent T lymphocyte adhesion to fibronectin through the binding of its fnIII 1-5 repeats to fibronectin. Eur J Immunol 1999; 29:1435-47; PMID:10359097; http://dx.doi.org/10.1002/(SICI)1521-4141(199905)29:05%3c1435::AID-IMMU1435%3e3.0.CO;2-N
   PubMedGoogle Scholar
• Garcion E, Halilagic A, Faissner A, ffrench-Constant C. Generation of an environmental niche for neural stem cell development by the extracellular matrix molecule tenascin C. Development 2004; 131:3423-32; PMID:15226258; http://dx.doi.org/10.1242/dev.01202
   PubMed Web of Science ®Google Scholar
• Garcion E, Faissner A, ffrench-Constant C. Knockout mice reveal a contribution of the extracellular matrix molecule tenascin-C to neural precursor proliferation and migration. Development 2001; 128:2485-96; PMID:11493565
   PubMed Web of Science ®Google Scholar
• Klein G, Beck S, Muller CA. Tenascin is a cytoadhesive extracellular matrix component of the human hematopoietic microenvironment. J Cell Biol 1993; 123:1027-35; PMID:7693718; http://dx.doi.org/10.1083/jcb.123.4.1027
   PubMed Web of Science ®Google Scholar
• Seiffert M, Beck SC, Schermutzki F, Muller CA, Erickson HP, Klein G. Mitogenic and adhesive effects of tenascin-C on human hematopoietic cells are mediated by various functional domains. Matrix Biol 1998; 17:47-63; PMID:9628252; http://dx.doi.org/10.1016/S0945-053X(98)90124-X
   PubMed Web of Science ®Google Scholar
• Yokosaki Y, Palmer EL, Prieto AL, Crossin KL, Bourdon MA, Pytela R, Sheppard D. The integrin α 9 β 1 mediates cell attachment to a non-RGD site in the third fibronectin type III repeat of tenascin. J Biol Chem 1994; 269:26691-6; PMID:7523411
   PubMed Web of Science ®Google Scholar
• Nakamura-Ishizu A, Okuno Y, Omatsu Y, Okabe K, Morimoto J, Uede T, Nagasawa T, Suda T, Kubota Y. Extracellular matrix protein tenascin-C is required in the bone marrow microenvironment primed for hematopoietic regeneration. Blood 2012; 119:5429-37; PMID:22553313; http://dx.doi.org/10.1182/blood-2011-11-393645
   PubMedGoogle Scholar
• Tucker RP, Ferralli J, Schittny JC, Chiquet-Ehrismann R. Tenascin-C and tenascin-W in whisker follicle stem cell niches: possible roles in regulating stem cell proliferation and migration. J Cell Sci 2013; 126:5111-5; PMID:24101721; http://dx.doi.org/10.1242/jcs.134650
   PubMedGoogle Scholar
• Ellis SL, Heazlewood SY, Williams B, Reitsma AJ, Grassinger J, Borg J, Heazlewood CK, Chidgey AP, Nilsson SK. The role of Tenascin C in the lymphoid progenitor cell niche. Exp Hematol 2013; 41:1050-61; PMID:24084079; http://dx.doi.org/10.1016/j.exphem.2013.09.009
   PubMed Web of Science ®Google Scholar
• Flenkenthaler F, Windschuttl S, Frohlich T, Schwarzer JU, Mayerhofer A, Arnold GJ. Secretome analysis of testicular peritubular cells: a window into the human testicular microenvironment and the spermatogonial stem cell niche in man. J Proteome Res 2014; 13:1259-69; PMID:24422521; http://dx.doi.org/10.1021/pr400769z
   PubMedGoogle Scholar
• Nakatsu MN, Vartanyan L, Vu DM, Ng MY, Li X, Deng SX. Preferential biological processes in the human limbus by differential gene profiling. PloS one 2013; 8:e61833; PMID:23630617; http://dx.doi.org/10.1371/journal.pone.0061833
   PubMedGoogle Scholar
• Descot A, Oskarsson T. The molecular composition of the metastatic niche. Exp Cell Res 2013; 319:1679-86; PMID:23707205
   PubMed Web of Science ®Google Scholar
• Barcellos-Hoff MH, Lyden D, Wang TC. The evolution of the cancer niche during multistage carcinogenesis. Nat Rev Cancer 2013; 13:511-8; PMID:23760023; http://dx.doi.org/10.1038/nrc3536
   PubMedGoogle Scholar
• Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17:1253-70; PMID:12756227; http://dx.doi.org/10.1101/gad.1061803
   PubMed Web of Science ®Google Scholar
• Oskarsson T, Massague J. Extracellular matrix players in metastatic niches. EMBO J 2012; 31:254-6; PMID:22179697; http://dx.doi.org/10.1038/emboj.2011.469
   PubMed Web of Science ®Google Scholar
• Wagner KU, Rui H. Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. J Mammary Gland Biol Neoplasia 2008; 13:93-103; PMID:18228120; http://dx.doi.org/10.1007/s10911-008-9062-z
   PubMed Web of Science ®Google Scholar
• Ruiz C, Huang W, Hegi ME, Lange K, Hamou MF, Fluri E, Oakeley EJ, Chiquet-Ehrismann R, Orend G. Growth promoting signaling by tenascin-C [corrected]. Cancer Res 2004; 64:7377-85; PMID:15492259; http://dx.doi.org/10.1158/0008-5472.CAN-04-1234
   PubMed Web of Science ®Google Scholar
• Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1:313-23; PMID:18371365; http://dx.doi.org/10.1016/j.stem.2007.06.002
   PubMed Web of Science ®Google Scholar
• Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-15; PMID:18485877; http://dx.doi.org/10.1016/j.cell.2008.03.027
   PubMed Web of Science ®Google Scholar
• Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, Huelsken J. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012; 481:85-9; http://dx.doi.org/10.1038/nature10694
   PubMed Web of Science ®Google Scholar
• Kii I, Nishiyama T, Li M, Matsumoto K, Saito M, Amizuka N, Kudo A. Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J Biol Chem 2010; 285:2028-39; PMID:19887451; http://dx.doi.org/10.1074/jbc.M109.051961
   PubMed Web of Science ®Google Scholar
• Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012; 150:165-78; PMID:22770218; http://dx.doi.org/10.1016/j.cell.2012.04.042
   PubMed Web of Science ®Google Scholar
• Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, Gao S, Puigserver P, Brugge JS. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009; 461:109-13; PMID:19693011; http://dx.doi.org/10.1038/nature08268
   PubMed Web of Science ®Google Scholar
• Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, André S, Piccart M, Campone M, Brain E, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009; 15:68-74; http://dx.doi.org/10.1038/nm.1908
   PubMed Web of Science ®Google Scholar
• Gong XG, Lv YF, Li XQ, Xu FG, Ma QY. Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells. Biol Pharm Bull 2010; 33:1261-7; PMID:20686216; http://dx.doi.org/10.1248/bpb.33.1261
   PubMed Web of Science ®Google Scholar
• Wang B, Liu K, Lin HY, Bellam N, Ling S, Lin WC. Fourteen-3-3Tau regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer. Mol Cell Biol 2010; 30:1508-27; PMID:20086099; http://dx.doi.org/10.1128/MCB.01335-09
   PubMedGoogle Scholar
• Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Klijn JG, Sleijfer S, Foekens JA, et al. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res 2008; 14:5555-64; PMID:18765548; http://dx.doi.org/10.1158/1078-0432.CCR-08-0555
   PubMed Web of Science ®Google Scholar